No Data
No Data
Huaan Securities: The chemical industry is under pressure in the cycle, repairs are expected, and the rebound in supply-side helps the recovery of the industry.
With the gradual economic recovery, continuous optimization of supply-side reform, the chemical industry is the strongest spear in the pro-cyclical phase, with a global competitive advantage, and the industry is expected to start an upturn cycle of prosperity.
Express News | Huaheng Biotechnology has signed a strategic cooperation agreement with ZxCredit and WangFanxin.
Express News | Star Market closing review: SSE Science and Technology Innovation Board 50 Index fell by 1.33%. Biopharmaceutical and photovoltaic sectors are feeling low.
Express News | Huaheng Bioscience: Plans to adjust the scheme for issuing A-share stocks to specific entities in 2022.
Huaheng Biotechnology (688639): Q2 performance is under pressure, waiting for new product volume.
On August 28, 2024, Henghua Biotechnology released its 2024 interim report. The company achieved a revenue of 1.016 billion yuan in H1 2024, a year-on-year growth of 19.57%; the net income attributable to the parent company was 0.15 billion yuan.
Huaheng Biology (688639): Short-term performance under pressure, long-term growth prospects clear.
The company's 1H24 performance is lower than our expectations. The company announced that in 1H24, it achieved revenue of 1.016 billion yuan, a year-on-year increase of 20% but a quarter-on-quarter decrease of 7%. The net income attributable to shareholders was 0.15 billion yuan, a year-on-year decrease of 22% and a quarter-on-quarter decrease of 42%. Among them, ...
No Data
No Data